SCHEMBL2095602

SCHEMBL2095602

Cc1ccccc1C([O])c1ccccc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.54
TSHR P16473 2/20 0.47
ACHE P22303 2/20 0.47
ACP3 P15309 1/20 0.45
ALDH1A1 P00352 3/20 0.43
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
GAA P10253 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CYP3A4 P08684 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP2D6 P10635 2/20 0.35
SLC22A2 O15244 1/20 0.35
SLC22A1 O15245 1/20 0.35
GRIN2D O15399 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29403593 0.81 ESR1 (0.52) ESR1TSHRACHEACP3ALDH1A1
SCHEMBL6220718 0.81 ESR1 (0.52) ESR1TSHRACHEACP3ALDH1A1
SCHEMBL16308863 0.81 ESR1 (0.52) ESR1TSHRACHEACP3ALDH1A1
SCHEMBL30647211 0.81 ESR1 (0.52) ESR1TSHRACHEACP3ALDH1A1
SCHEMBL16308826 0.81 ESR1 (0.52) ESR1TSHRACHEACP3ALDH1A1
SCHEMBL624799 0.81 ESR1 (0.52) ESR1TSHRACHEACP3ALDH1A1
SCHEMBL7380183 0.79 ESR1 (0.50) ESR1TSHRACHEACP3ALDH1A1
SCHEMBL4430667 0.78 ESR1 (0.54) ESR1TSHRACHEACP3ALDH1A1
SCHEMBL1248016 0.78 ESR1 (0.54) ESR1TSHRACHEACP3ALDH1A1
SCHEMBL18241957 0.77 ESR1 (0.48) ESR1TSHRACHEACP3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
US-7268247-B2 Process for the preparation of phenylmalonic acid dinitriles SYNGENTA CROP PROTECTION, INC. (US) 2007-09-11 US disclosed
US-20060135805-A1 Process for the preparation of phenylmalonic acid dinitriles SYNGENTA CROP PROTECTION, INC. 2006-06-22 US disclosed
EP-1567482-A1 PROCESS FOR THE PREPARATION OF PHENYLMALONIC ACID DINITRILES Syngenta Participations AG (CH) 2005-08-31 EP disclosed
WO-2004050607-A1 PROCESS FOR THE PREPARATION OF PHENYLMALONIC ACID DINITRILES SYNGENTA PARTICIPATIONS AG (CH) 2004-06-17 WO disclosed
US-6441233-B1 CARBONYLATION, AMIDATION; IN PRESENCE OF ACYLATION CATALYST SOLVIAS AG (CH) 2002-08-27 US disclosed
EP-1185506-A1 SUBSTITUTED ARYLMALONIC ACID DINITRILES AS INTERMEDIATES FOR THE PREPARATION OF HERBICIDES Syngenta Participations AG (CH) 2002-03-13 EP disclosed
EP-1140796-A1 PROCESS FOR THE PREPARATION OF AROMATIC CARBOXYLIC ACID AMIDES Solvias AG (CH) 2001-10-10 EP disclosed
WO-2000078712-A1 SUBSTITUTED ARYLMALONIC ACID DINITRILES AS INTERMEDIATES FOR THE PREPARTION OF HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2000-12-28 WO disclosed
WO-2000037428-A1 PROCESS FOR THE PREPARATION OF AROMATIC CARBOXYLIC ACID AMIDES SOLVIAS AG (CH) 2000-06-29 WO disclosed
EP-0073413-A2 Acylphosphine oxide compounds and their use BASF Aktiengesellschaft (DE) 1983-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ESR1 1871/4885TSHR 162/4885ACHE 4734/4885
US-20060135805-A1 Process for the preparation of phenylmalonic acid dinitriles ME1, PDK2, PDK4 ESR1 4657/4885TSHR 4577/4885ACHE 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.